Example of Therapeutic Advances in Chronic Disease format
Recent searches

Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format Example of Therapeutic Advances in Chronic Disease format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Therapeutic Advances in Chronic Disease — Template for authors

Publisher: SAGE
Categories Rank Trend in last 3 yrs
Medicine (miscellaneous) #92 of 238 down down by 84 ranks
journal-quality-icon Journal quality:
Good
calendar-icon Last 4 years overview: 174 Published Papers | 691 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 01/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Taylor and Francis

Quality:  
High
CiteRatio: 6.8
SJR: 0.866
SNIP: 1.035
open access Open Access
recommended Recommended

SAGE

Quality:  
High
CiteRatio: 8.8
SJR: 1.436
SNIP: 1.725
open access Open Access

SAGE

Quality:  
High
CiteRatio: 1.2
SJR: 0.254
SNIP: 0.638
open access Open Access

SAGE

Quality:  
High
CiteRatio: 5.8
SJR: 0.935
SNIP: 1.598

Journal Performance & Insights

CiteRatio

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

A measure of average citations received per peer-reviewed paper published in the journal.

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

4.0

47% from 2019

CiteRatio for Therapeutic Advances in Chronic Disease from 2016 - 2020
Year Value
2020 4.0
2019 7.6
2018 9.5
2017 10.4
2016 7.2
graph view Graph view
table view Table view

1.027

26% from 2019

SJR for Therapeutic Advances in Chronic Disease from 2016 - 2020
Year Value
2020 1.027
2019 1.384
2018 1.516
2017 1.895
2016 1.266
graph view Graph view
table view Table view

1.359

30% from 2019

SNIP for Therapeutic Advances in Chronic Disease from 2016 - 2020
Year Value
2020 1.359
2019 1.945
2018 2.059
2017 2.032
2016 1.4
graph view Graph view
table view Table view

insights Insights

  • CiteRatio of this journal has decreased by 47% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

insights Insights

  • SJR of this journal has decreased by 26% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has decreased by 30% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Therapeutic Advances in Chronic Disease

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

SAGE

Therapeutic Advances in Chronic Disease

Approved by publishing and review experts on SciSpace, this template is built as per for Therapeutic Advances in Chronic Disease formatting guidelines as mentioned in SAGE author instructions. The current version was created on 01 Jun 2020 and has been used by 337 authors to write and format their manuscripts to this journal.

Medicine

i
Last updated on
01 Jun 2020
i
ISSN
2040-6223
i
Impact Factor
Low - 0.381
i
Open Access
No
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
SageV
i
Citation Type
Numbered (Superscripted)
25
i
Bibliography Example
Blonder GE, Tinkham M and Klapwijk TM. Transition from metallic to tunneling regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion. Phys. Rev. B 1982; 25(7): 4515–4532. URL 10.1103/PhysRevB.25.4515.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1177/2040622315609251
Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease.
Leena George1, Christopher E. Brightling2

Abstract:

The chronic lung diseases, asthma and chronic obstructive pulmonary disease (COPD), are common affecting over 500 million people worldwide and causing substantial morbidity and mortality. Asthma is typically associated with Th2-mediated eosinophilic airway inflammation, in contrast to neutrophilic inflammation observed common... The chronic lung diseases, asthma and chronic obstructive pulmonary disease (COPD), are common affecting over 500 million people worldwide and causing substantial morbidity and mortality. Asthma is typically associated with Th2-mediated eosinophilic airway inflammation, in contrast to neutrophilic inflammation observed commonly in COPD. However, there is increasing evidence that the eosinophil might play an important role in 10-40% of patients with COPD. Consistently in both asthma and COPD a sputum eosinophilia is associated with a good response to corticosteroid therapy and tailored strategies aimed to normalize sputum eosinophils reduce exacerbation frequency and severity. Advances in our understanding of the multistep paradigm of eosinophil recruitment to the airway, and the consequence of eosinophilic inflammation, has led to the development of new therapies to target these molecular pathways. In this article we discuss the mechanisms of eosinophilic trafficking, the tools to assess eosinophilic airway inflammation in asthma and COPD during stable disease and exacerbations and review current and novel anti-eosinophilic treatments. read more read less

Topics:

COPD (58%)58% related to the paper, Asthma (56%)56% related to the paper, Eosinophilic (55%)55% related to the paper, Eosinophil (53%)53% related to the paper, Exacerbation (53%)53% related to the paper
View PDF
228 Citations
open accessOpen access Journal Article DOI: 10.1177/2040622311430006
Evidence for a protective effect of polyphenols-containing foods on cardiovascular health: an update for clinicians

Abstract:

Growing evidence suggests that polyphenols could be serious candidates to explain the protective effects of plant-derived foods and beverages. Based on current studies, a general consensus has been achieved to sustain the hypothesis that the specific intake of foods and beverages containing relatively high concentrations of f... Growing evidence suggests that polyphenols could be serious candidates to explain the protective effects of plant-derived foods and beverages. Based on current studies, a general consensus has been achieved to sustain the hypothesis that the specific intake of foods and beverages containing relatively high concentrations of flavonoids may play a meaningful role in reducing cardiovascular disease (CVD) risk through an improvement in vascular function and a modulation of inflammation. This review aims at providing an update on the effects of the consumption of polyphenols-rich foods on intermediate clinical markers of CVD in humans, namely cholesterolemia, blood pressure, endothelial function and platelet function. To date, on the basis of clinical studies, the demonstration is particularly convincing for flavonoids from cocoa-derived products and to a lesser extent for those of tea. While additional studies in this area are clearly needed, incorporating plant foods that are rich in flavanols in the diet of healthy individuals could help to reduce CVD risk. For flavonoids from fruits such as berries, pomegranate, grapes or citrus fruits and those from beverages such as red wine or coffee, the evidence is so far inconclusive. This is primarily due to the limited number and the weakness of experimental designs of the studies performed with these dietary sources. Future long-term well-designed investigations with polyphenols-rich foods but also with isolated phenolic compounds would provide valuable information to establish public health recommendations on polyphenols, taking into account both the nature of the compounds and the optimal dose, for cardiovascular health protection. read more read less
View PDF
226 Citations
open accessOpen access Journal Article DOI: 10.1177/2040622315590318
Obstructive sleep apnoea syndrome and its management
Lucia Spicuzza, Daniela Caruso1, Giuseppe Di Maria1

Abstract:

Obstructive sleep apnoea (OSA) is a common disorder characterized by repetitive episodes of nocturnal breathing cessation due to upper airway collapse. OSA causes severe symptoms, such as excessive daytime somnolence, and is associated with a significant cardiovascular morbidity and mortality. Different treatment options are ... Obstructive sleep apnoea (OSA) is a common disorder characterized by repetitive episodes of nocturnal breathing cessation due to upper airway collapse. OSA causes severe symptoms, such as excessive daytime somnolence, and is associated with a significant cardiovascular morbidity and mortality. Different treatment options are now available for an effective management of this disease. After more than three decades from its first use, continuous positive airway pressure (CPAP) is still recognized as the gold standard treatment. Nasal CPAP (nCPAP) is highly effective in controlling symptoms, improving quality of life and reducing the clinical sequelae of sleep apnoea. Other positive airway pressure modalities are available for patients intolerant to CPAP or requiring high levels of positive pressure. Mandibular advancement devices, particularly if custom made, are effective in mild to moderate OSA and provide a viable alternative for patients intolerant to CPAP therapy. The role of surgery remains controversial. Uvulopalatopharyngoplasty is a well established procedure and can be considered when treatment with CPAP has failed, whereas maxillar-mandibular surgery can be suggested to patients with a craniofacial malformation. A number of minimally invasive procedures to treat snoring are currently under evaluation. Weight loss improves symptoms and morbidity in all patients with obesity and bariatric surgery is an option in severe obesity. A multidisciplinary approach is necessary for an accurate management of the disease. read more read less

Topics:

Continuous positive airway pressure (63%)63% related to the paper, Positive airway pressure (61%)61% related to the paper, Uvulopalatopharyngoplasty (56%)56% related to the paper, Oral appliance (53%)53% related to the paper
View PDF
202 Citations
open accessOpen access Journal Article DOI: 10.1177/2040622314552071
Treatment of painful diabetic neuropathy.
Saad Ahmed Javed1, Ioannis N. Petropoulos, Uazman Alam2, Rayaz A. Malik2

Abstract:

Painful diabetic neuropathy (PDN) is a debilitating consequence of diabetes that may be present in as many as one in five patients with diabetes. The objective assessment of PDN is difficult, making it challenging to diagnose and assess in both clinical practice and clinical trials. No single treatment exists to prevent or re... Painful diabetic neuropathy (PDN) is a debilitating consequence of diabetes that may be present in as many as one in five patients with diabetes. The objective assessment of PDN is difficult, making it challenging to diagnose and assess in both clinical practice and clinical trials. No single treatment exists to prevent or reverse neuropathic changes or to provide total pain relief. Treatment of PDN is based on three major approaches: intensive glycaemic control and risk factor management, treatments based on pathogenetic mechanisms, and symptomatic pain management. Clinical guidelines recommend pain relief in PDN through the use of antidepressants such as amitriptyline and duloxetine, the γ-aminobutyric acid analogues gabapentin and pregabalin, opioids and topical agents such as capsaicin. Of these medications, duloxetine and pregabalin were approved by the US Food and Drug Administration (FDA) in 2004 and tapentadol extended release was approved in 2012 for the treatment of PDN. Proposed pathogenetic treatments include α-lipoic acid (stems reactive oxygen species formation), benfotiamine (prevents vascular damage in diabetes) and aldose-reductase inhibitors (reduces flux through the polyol pathway). There is a growing need for studies to evaluate the most potent drugs or combinations for the management of PDN to maximize pain relief and improve quality of life. A number of agents are potential candidates for future use in PDN therapy, including Nav 1.7 antagonists, N-type calcium channel blockers, NGF antibodies and angiotensin II type 2 receptor antagonists. read more read less

Topics:

Pregabalin (56%)56% related to the paper, Gabapentin (55%)55% related to the paper, Duloxetine (52%)52% related to the paper
177 Citations
open accessOpen access Journal Article DOI: 10.1177/2040622315579059
Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review.

Abstract:

Current pharmacotherapies for major depressive disorder (MDD) and bipolar depression (BDep) have a distinct lag of onset that can generate great distress and impairment in patients. Furthermore, as demonstrated by several real-world effectiveness trials, their efficacy is limited. All approved antidepressant medications for M... Current pharmacotherapies for major depressive disorder (MDD) and bipolar depression (BDep) have a distinct lag of onset that can generate great distress and impairment in patients. Furthermore, as demonstrated by several real-world effectiveness trials, their efficacy is limited. All approved antidepressant medications for MDD primarily act through monoaminergic mechanisms, agonists or antagonists with varying affinities for serotonin, norepinephrine and dopamine. The glutamate system has received much attention in recent years as an avenue for developing novel therapeutics. A single subanesthetic dose infusion of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has been shown to have rapid and potent antidepressant effects in treatment-resistant MDD and BDep. In a reverse translational framework, ketamine’s clinical efficacy has inspired many preclinical studies to explore glutamatergic mechanisms of antidepressant action. These studies have revealed enhanced synaptic plasticity/synaptogenesis via numerous molecular and cellular mechanisms: release of local translational inhibition of brain-derived neurotrophic factor and secretion from dendritic spines, mammalian target of rapamycin activation and glycogen synthase kinase-3 inhibition. Current efforts are focused on extending ketamine’s antidepressant efficacy, uncovering the neurobiological mechanisms responsible for ketamine’s antidepressant activity in biologically enriched subgroups, and identifying treatment response biomarkers to personalize antidepressant selection. Other NMDA receptor antagonists have been studied both preclinically and clinically, which have revealed relatively modest antidepressant effects compared with ketamine but potentially other favorable characteristics, for example, decreased dissociative or psychotomimetic effects; therefore, there is great interest in developing novel glutamatergic antidepressants with greater target specificity and/or decreased adverse effects. read more read less

Topics:

Antidepressant (55%)55% related to the paper, NMDA receptor (53%)53% related to the paper, Receptor antagonist (52%)52% related to the paper, Treatment-resistant depression (51%)51% related to the paper
View PDF
168 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Therapeutic Advances in Chronic Disease.

It automatically formats your research paper to SAGE formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Therapeutic Advances in Chronic Disease format uses SageV citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Therapeutic Advances in Chronic Disease in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Therapeutic Advances in Chronic Disease guidelines and auto format it.

2. Do you follow the Therapeutic Advances in Chronic Disease guidelines?

Yes, the template is compliant with the Therapeutic Advances in Chronic Disease guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Therapeutic Advances in Chronic Disease?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Therapeutic Advances in Chronic Disease citation style.

4. Can I use the Therapeutic Advances in Chronic Disease templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Therapeutic Advances in Chronic Disease.

5. Can I use a manuscript in Therapeutic Advances in Chronic Disease that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Therapeutic Advances in Chronic Disease that you can download at the end.

6. How long does it usually take you to format my papers in Therapeutic Advances in Chronic Disease?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Therapeutic Advances in Chronic Disease.

7. Where can I find the template for the Therapeutic Advances in Chronic Disease?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Therapeutic Advances in Chronic Disease's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Therapeutic Advances in Chronic Disease's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Therapeutic Advances in Chronic Disease an online tool or is there a desktop version?

SciSpace's Therapeutic Advances in Chronic Disease is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Therapeutic Advances in Chronic Disease?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Therapeutic Advances in Chronic Disease?”

11. What is the output that I would get after using Therapeutic Advances in Chronic Disease?

After writing your paper autoformatting in Therapeutic Advances in Chronic Disease, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Therapeutic Advances in Chronic Disease's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Therapeutic Advances in Chronic Disease?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Therapeutic Advances in Chronic Disease. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Therapeutic Advances in Chronic Disease?

The 5 most common citation types in order of usage for Therapeutic Advances in Chronic Disease are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Therapeutic Advances in Chronic Disease?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Therapeutic Advances in Chronic Disease's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Therapeutic Advances in Chronic Disease in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Therapeutic Advances in Chronic Disease Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Therapeutic Advances in Chronic Disease formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template